IQVIA Holdings Inc. (NYSE:IQV) Holdings Trimmed by Swiss National Bank

Swiss National Bank reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 514,980 shares of the medical research company's stock after selling 25,800 shares during the quarter. Swiss National Bank owned approximately 0.28% of IQVIA worth $101,199,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Impax Asset Management Group plc lifted its position in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Assetmark Inc. increased its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Covestor Ltd raised its position in IQVIA by 34.4% in the third quarter. Covestor Ltd now owns 246 shares of the medical research company's stock valued at $59,000 after purchasing an additional 63 shares during the period. Apollon Wealth Management LLC boosted its position in shares of IQVIA by 9.6% in the third quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company's stock worth $1,155,000 after buying an additional 427 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of IQVIA during the 3rd quarter valued at about $230,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Stock Performance

IQVIA stock traded down $1.75 during midday trading on Wednesday, reaching $186.80. 1,008,388 shares of the stock traded hands, compared to its average volume of 1,227,564. The firm has a fifty day moving average price of $196.06 and a two-hundred day moving average price of $209.52. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.34. The firm has a market cap of $32.93 billion, a price-to-earnings ratio of 24.91, a PEG ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.